Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2025
    • The 2024 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Educational Assets
    • Manufacturer Search
    • Podcasts
    • Print Subscription
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Video
  • 2025 Leadership
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertise
  • Subscribe

MedTech Memoirs: Inhalable Insulin Flops…Twice

February 4, 2016 By Sam Brusco

You would think that inhalable insulin should be a million-dollar idea, right? No longer would diabetics have to worry about regular injections or an insulin pump to keep track of. Administering the medicine would be simple and virtually painless—a diabetic’s dream.

But both major efforts to successfully get an inhalable insulin device into the market in the last decade have failed. Miserably. And these aren’t small projects coming from ambitious startup companies: the first major attempt was made by Pfizer in 2006, and the second by Sanofi in early 2015.

Pfizer partnered with Nektar Therapeutics to develop Exubera, dry powder form of insulin delivered with an inhaler. Since it was the first type of insulin that didn’t require injection, analysts projected one to four billion dollars in annual sales. But after nine months of sales, the product had only garnered 12 million dollars.

Many attribute Exubera’s failure to Pfizer. They didn’t contact Nektar at all before breaking the news, so Nektar learned about it via the newswire, just like everyone else. Some believe Pfizer thought Exubera would sell itself, and marketing became inadequate as a result—reasons cited include a lack of samples, late TV ads, and a general lack of exciting advertising. Others cite that physicians simply didn’t want to take on a new product.

But most agree that the issue lied in the inhaler’s design specifically its size. Exubera was about as large as a flashlight, and even larger when expanded to ready position. The inhalation technology wasn’t the issue—to operate, the user simply loads small blister packets of insulin for each dose and triggers the mechanism for inhalation.

The problem was that many were embarrassed to use Exubera in public because it looked like a bong. That one’s on Nektar: they were the one to come up with the inhaler design.

I can see why someone might have reservations about inhaling this in public. (Credit: Science Museum Group)

Fast forward almost a decade to February 2015, when Sanofi launched Afrezza, its iteration of an inhalable insulin device, this time developed by MannKind. All signs pointed to it being a success: the delivery device was smaller (about the size of a whistle) and Afrezza was marketed more aggressively than Exubera.

But a month ago, Sanofi announced it was backing out of the partnership due to poor sales—only about five million dollars in the first nine months of marketing. It performed more poorly than Exubera, and the issue of the product being mistaken for a bong couldn’t have happened this time. It was much less conspicuous!

Pictured: much less likely to be confused with a bong. (Credit: MannKind)

For starters, inhalable insulin carries some risks. Exubera exhibited some of the same issues: inhaled insulin can cause constriction of the lungs’ airways in patients with COPD and asthma.

However, the main issue (once again) looked to be challenges with the technology’s adoption by the healthcare community. One physician cited his reasoning in July 2015 in BioPharma Dive: “I would not write it for two reasons: 1) The Exubera problem with the lungs and Afrezza’s boxed warning regarding the same issue, and 2) What a pain it is trying to change a patient from the needle-based insulin to inhaled insulin because of dosing. A mistake in equivalency can mean hypoglycemia. I imagine that’s why most doctors will not switch patients. The only time I would consider prescribing Afrezza would be for a new patient that I can get used to it slowly, or someone who is very scared of needles.”

Sanofi will continue marketing Afrezza until April 2016, but after that MannKind is on its own. It’s really a shame—inhalable insulin delivery would be a breath of fresh air for diabetics who are administered daily injections.

The lung problems should be fixable: pharma companies developing the powdered insulin need to spend more time in the lab finding a solution that doesn’t impede lung function. But adoption by the healthcare community is a major hurdle that can’t easily be resolved, and has so far derailed two insulin inhalers put out by very large companies. And unfortunately, unless this is resolved, inhalable insulin may never catch on.

 

What do you think can be done to help the healthcare community embrace inhalable insulin? Comment below!

Related Articles Read More >

An illustration of the Endogenex ReCET system inside a patient.
This minimally invasive diabetes device delivers pulsed field energy in the gut
UCSD diabetic kidney disease.
New imaging technology offers noninvasive 3D view of diabetic kidney disease
May 2025 edition: Inhalable vaccine delivery, type 2 diabetes tech and Medtronic aDBS
A portrait of former Insulet Chief Technology Officer Mark Field.
Ex-Insulet CTO Mark Field has a new job in medtech with ITJ
“mdo
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest medical device business news, application and technology trends.

DeviceTalks Weekly

See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech100 Index
  • Medical Tubing + Extrusion
  • Medical Design Sourcing
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to our E-Newsletter
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2025 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2025
    • The 2024 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Educational Assets
    • Manufacturer Search
    • Podcasts
    • Print Subscription
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Video
  • 2025 Leadership
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertise
  • Subscribe